Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Payables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Payables for 16 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 2.03% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 2.03% decrease, with the full-year FY2024 number at $4.8 million, down 13.81% from a year prior.
  • Payables was $5.2 million for Q3 2025 at Harvard Bioscience, up from $4.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.5 million in Q2 2021 to a low of $4.7 million in Q2 2023.
  • A 5-year average of $5.7 million and a median of $5.7 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 31.28% in 2022, then tumbled 30.75% in 2023.
  • Harvard Bioscience's Payables stood at $4.9 million in 2021, then surged by 31.28% to $6.4 million in 2022, then fell by 13.85% to $5.6 million in 2023, then decreased by 13.81% to $4.8 million in 2024, then rose by 8.13% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Payables are $5.2 million (Q3 2025), $4.7 million (Q2 2025), and $4.8 million (Q1 2025).